GlassScriptPhysician profile
Nattapron Tun
NPI 1225597388
$2,759.62
in general payments reported to CMS, 2019-2025
25 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $596 · 2024: $1,281 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.21 |
| Education | $269.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $536.07 | 2022-2023 | Tukysa, Adcetris |
| Genzyme Corporation | $490.76 | 2023-2025 | |
| Kite Pharma, INC. | $287.09 | 2024-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $229.50 | 2024-2025 | Enhertu |
| Pfizer INC. | $193.18 | 2024-2025 | |
| Celgene Corporation | $141.58 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Astellas Pharma US INC | $124.77 | 2024 | Xospata |
| Alexion Pharmaceuticals, INC. | $111.74 | 2023-2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $86.82 | 2024-2025 | Keytruda |
| Daiichi Sankyo INC. | $80.37 | 2024 | Enhertu |
| Eisai INC. | $74.44 | 2024-2025 | |
| Genentech USA, INC. | $55.10 | 2024-2025 | Tecentriq, Columvi |
| Agios Pharmaceuticals, INC. | $44.69 | 2024-2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $39.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $36.96 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.87 | 2025 | Jaypirca, Verzenio |
| Myriad Genetic Laboratories, INC. | $27.84 | 2024 | Myrisk |
| Karyopharm Therapeutics INC. | $24.80 | 2025 | Xpovio |
| Mirati Therapeutics, INC. | $23.61 | 2024 | Krazati |
| Abbvie INC. | $22.72 | 2024 | |
| Stemline Therapeutics INC. | $22.43 | 2025 | Elzonris |
| Gilead Sciences, INC. | $20.72 | 2025 | Trodelvy |
| Array Biopharma INC | $18.36 | 2025 | Mektovi, Braftovi, Xalkori |
| Kyowa Kirin, INC. | $18.31 | 2025 | |
| Iovance Biotherapeutics, INC. | $14.49 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nattapron Tun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.